Avalon Advisors Has Lowered Its Pfizer Cmn (PFE) Position, Triple-s Management (GTS) Has 0.72 Sentiment

June 19, 2017 - By Hazel Jackson

Triple-S Management Corporation operates as a managed care company. The company has market cap of $400.62 million. The Firm offers a range of managed care and related products in the commercial, Medicaid and Medicare markets. It has a 41.55 P/E ratio. The Company’s divisions include Managed Care, Life Insurance, and Property and Casualty Insurance.

Avalon Advisors Llc decreased Pfizer Inc. Cmn (PFE) stake by 2.67% reported in 2016Q4 SEC filing. Avalon Advisors Llc sold 38,674 shares as Pfizer Inc. Cmn (PFE)’s stock declined 3.45%. The Avalon Advisors Llc holds 1.41 million shares with $45.88M value, down from 1.45 million last quarter. Pfizer Inc. Cmn now has $198.58B valuation. The stock rose 0.65% or $0.22 reaching $33.19. About 10.33M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since June 19, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $19,536 activity.

About 82,894 shares traded or 4.29% up from the average. Triple-S Management Corp. (GTS) has declined 25.70% since June 19, 2016 and is downtrending. It has underperformed by 42.40% the S&P500.

Healthinvest Partners Ab holds 6.95% of its portfolio in Triple-S Management Corp. for 364,156 shares. Lakewood Capital Management Lp owns 846,409 shares or 0.79% of their US portfolio. Moreover, Heartland Advisors Inc has 0.6% invested in the company for 520,760 shares. The Illinois-based Cna Financial Corp has invested 0.27% in the stock. Pzena Investment Management Llc, a New York-based fund reported 2.10 million shares.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 1. They expect $0.65 EPS, up 1.56% or $0.01 from last year’s $0.64 per share. PFE’s profit will be $3.89 billion for 12.77 P/E if the $0.65 EPS becomes a reality. After $0.69 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -5.80% negative EPS growth.

Since February 27, 2017, it had 0 insider buys, and 5 sales for $5.16 million activity. $153,855 worth of Pfizer Inc. (NYSE:PFE) was sold by JOHNSON RADY A on Friday, March 10. Dolsten Mikael also sold $2.02 million worth of Pfizer Inc. (NYSE:PFE) shares. 20,000 shares were sold by LANKLER DOUGLAS M, worth $693,200 on Thursday, March 2. $1.23 million worth of Pfizer Inc. (NYSE:PFE) was sold by HILL CHARLES H on Thursday, March 9.

Among 20 analysts covering Pfizer (NYSE:PFE), 7 have Buy rating, 1 Sell and 12 Hold. Therefore 35% are positive. Pfizer had 45 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, June 14. The firm has “Neutral” rating given on Friday, March 24 by Societe Generale. The stock of Pfizer Inc. (NYSE:PFE) earned “Sell” rating by Citigroup on Tuesday, May 16. Morgan Stanley upgraded the stock to “Overweight” rating in Friday, October 2 report. Argus Research maintained the shares of PFE in report on Tuesday, November 3 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, November 25 by SunTrust. The firm has “Neutral” rating given on Friday, April 7 by Morgan Stanley. The firm has “Overweight” rating given on Saturday, September 5 by Piper Jaffray. The rating was maintained by S&P Research with “Hold” on Wednesday, October 28. On Tuesday, September 13 the stock rating was maintained by Jefferies with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: